Table 1.
The relationship between AAPR groups and clinicopathological parameters in the present BC cohort (n = 199).
| Covariates | Total | AAPR group | P-value | ||
|---|---|---|---|---|---|
| Low | Medium | High | |||
| Number of patients | 199 | 35 | 61 | 103 | |
| Age, Mean ± SD | 64.0 ± 8.7 | 65.0 ± 9.2 | 65.1 ± 8.2 | 62.9 ± 8.8 | 0.227 |
| Age group, n (%) | 0.398 | ||||
| <67 | 124 (62.3) | 18 (51.4) | 36 (59) | 70 (68) | |
| 67-73 | 51 (25.6) | 11 (31.4) | 18 (29.5) | 22 (21.4) | |
| ≥74 | 24 (12.1) | 6 (17.1) | 7 (11.5) | 11 (10.7) | |
| Sex, n (%) | 0.591 | ||||
| Female | 40 (20.1) | 5 (14.3) | 14 (23) | 21 (20.4) | |
| Male | 159 (79.9) | 30 (85.7) | 47 (77) | 82 (79.6) | |
| BMI, Mean ± SD | 23.5 ± 3.9 | 21.8 ± 3.6 | 24.5 ± 3.9 | 23.6 ± 3.9 | 0.005* |
| Smoking history, n (%) | 0.038* | ||||
| No | 111 (55.8) | 20 (57.1) | 26 (42.6) | 65 (63.1) | |
| Yes | 88 (44.2) | 15 (42.9) | 35 (57.4) | 38 (36.9) | |
| ECOG-PS, n (%) | 0.505 | ||||
| 0 | 134 (67.3) | 26 (74.3) | 42 (68.9) | 66 (64.1) | |
| 1 | 43 (21.6) | 6 (17.1) | 10 (16.4) | 27 (26.2) | |
| 2 | 22 (11.1) | 3 (8.6) | 9 (14.8) | 10 (9.7) | |
| Diabetes, n (%) | 0.412 | ||||
| No | 164 (82.4) | 30 (85.7) | 47 (77) | 87 (84.5) | |
| Yes | 35 (17.6) | 5 (14.3) | 14 (23) | 16 (15.5) | |
| Hypertension, n (%) | 0.175 | ||||
| No | 165 (82.9) | 27 (77.1) | 55 (90.2) | 83 (80.6) | |
| Yes | 34 (17.1) | 8 (22.9) | 6 (9.8) | 20 (19.4) | |
| Chemotherapy, n (%) | 0.282 | ||||
| No | 164 (82.4) | 32 (91.4) | 50 (82) | 82 (79.6) | |
| Yes | 35 (17.6) | 3 (8.6) | 11 (18) | 21 (20.4) | |
| ASA classification, n (%) | 0.568 | ||||
| 1 | 40 (20.1) | 10 (28.6) | 13 (21.3) | 17 (16.5) | |
| 2 | 130 (65.3) | 20 (57.1) | 38 (62.3) | 72 (69.9) | |
| 3 | 29 (14.6) | 5 (14.3) | 10 (16.4) | 14 (13.6) | |
| T-stage, n (%) | 0.249 | ||||
| T1-T2 | 166 (83.4) | 26 (74.3) | 51 (83.6) | 89 (86.4) | |
| T3-T4 | 33 (16.6) | 9 (25.7) | 10 (16.4) | 14 (13.6) | |
| Lymph node status, n (%) | 0.15 | ||||
| Negative | 160 (80.4) | 24 (68.6) | 51 (83.6) | 85 (82.5) | 0.586 |
| Positive | 39 (19.6) | 11 (31.4) | 10 (16.4) | 18 (17.5) | |
| Tumor grade, n (%) | |||||
| Low | 117 (58.8) | 20 (57.1) | 33 (54.1) | 64 (62.1) | |
| High | 82 (41.2) | 15 (42.9) | 28 (45.9) | 39 (37.9) | |
| HGB, Median (IQR) | 130.0 (116.0, 143.0) | 127.0 (115.0, 138.0) | 132.0 (112.0, 143.0) | 131.0 (120.5, 143.0) | 0.388 |
| AAPR, Mean ± SD | 0.6 ± 0.2 | 0.3 ± 0.1 | 0.5 ± 0.1 | 0.8 ± 0.1 | < 0.001* |
*P < 0.05. BC, bladder cancer; AAPR, albumin-to-alkaline phosphatase ratio; ECOG-PS, Performance Status of East Cooperative Oncology Group; ASA, American Society of Anesthesiologists; HGB, Hemoglobin.